Brain Cancer


Glioblastoma multiforme (GBM) is the most common and aggressive of all primary brain cancer diagnosed in adults.

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain cancer diagnosed in adults, accounting for more than half of all brain cancers. Worldwide in 2018, almost 300,00 people were diagnosed for the first time with brain cancer and in the same year 240,000 people died from their disease. The outlook for people diagnosed with GBM is poor, with half of all patients surviving between 12-18 months, 25% for more than 12 months and only 5% surviving for 5 years. GBM develops from star-shaped connecting cells in the brain called astrocytes. Telix’s brain cancer program is focused on treatment with its TLX101 therapeutic.



About TLX101

TLX101 (4-iodo-[131I]-phenylalanine or 131I-IPA) is a new experimental therapeutic radiopharmaceutical being developed to treat glioblastoma (GBM). Cancer cells like those found in aggressive glioblastoma (GBM) tumours grow faster than normal cells and require more nutrients like glucose and amino acids to sustain this growth. TLX101 is designed to utilize this difference in nutrient requirement to target cancer cells with deadly radiation.


Current development activity

The combination of TLX101 and external beam radiation is currently being studied in a Phase I/II clinical trial called IPAX-1. The trial is being conducted at several hospital locations across Europe and Australia.


  • Baum RP, Kluge A, Gildehaus FJ, et al. Systemic endoradiotherapy with carrier-added 4-[131I]iodo- L- phenylalanine: Clinical proof-of-principle in refractory glioma. Nucl Med Mol Imaging 2011; 45: 299–307.
  • Verburg, F.A., Sweeney, R., Hänscheid, H., Dießl, S., Israel, I., Löhr, M. et al. Patients with recurrent glioblastoma multiforme. Initial experience with p-[131I]iodo-L-phenylalanine and external beam radiation therapy. Nuklearmedizin, 2013, 52(1): 36-42.
  • Jager, P.L., Vaalburg, W., Pruim, J., de Vries, E.G., Langen, K.J., Piers, D.A. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001, 42(3): 432-45.

None of Telix’s product pipeline has received marketing authorization in any jurisdiction. Any use of Telix products is on an investigational basis or for use in approved clinical trials.